Cadrenal Therapeutics Inc (CVKD)

$10.90 +2.09 (23.72%)
Market Cap 17.33M
Revenue (ttm) 0.00
Net Income (ttm) -10.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 74,900
Avg Vol 29,710
Day's Range N/A - N/A
Shares Out 1.97M
Stochastic %K 67%
Beta 0.93
Analysts Strong Sell
Price Target $35.67

Company Profile

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-...

Industry: Biotechnology
Sector: Healthcare
Phone: 904 300 0701
Address:
822 A1A North, Suite 306, Ponte Vedra, United States
Joby099
Joby099 Aug. 6 at 1:27 AM
$QBTS $CVKD $EQ $NVA $KULR
0 · Reply
PaidBashar
PaidBashar Aug. 5 at 10:44 PM
$CVKD wen financing
0 · Reply
BioTuesdays
BioTuesdays Aug. 5 at 2:11 PM
$CVKD has announced clinical trial initiation plans for its lead late-stage candidate, tecarfarin, for the treatment of patients with end-stage kidney disease (ESKD) transitioning to dialysis https://biotuesdays.com/2025/08/05/cadrenal-reveals-clinical-trial-plans-for-tecarfarin-in-eskd/
0 · Reply
Joby099
Joby099 Aug. 5 at 12:02 PM
$QBTS $CVKD $EQ $NVA $KULR
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 5 at 10:53 AM
WATCHLIST AUG 05 2025. $CVKD Cadrenal Therapeutics Announced Trial Initiation Plans For Tecarfarin For End-stage Kidney Disease Patients Who Are Transitioning To Dialysis. Enrollment Is Planned To Begin Later This Year And Will Include Patients With And Without Atrial Fibrillation $DD DuPont De Nemours On Track For Nov. 1 Spinoff Date For Electronics Business Creating New Independent, Publicly Traded Electronics Company "Qnity Electronics, Inc." $ATKR Atkore CEO Bill Waltz Announces Retirement Plans; Board Of Directors Begins Search For New Chief Executive $PRTA Chardan Capital Maintains Buy on Prothena Corp, Maintains $18 Price Target $PRAA PRA Group shares are trading higher after the company reported a year-over-year increase in Q2 GAAP EPS results and better-than-expected Q2 sales results.
0 · Reply
AnnaDona
AnnaDona Aug. 5 at 2:13 AM
$CVKD Volume picking up today. Heavy volume pouring in — something's brewing.
1 · Reply
MayraDono
MayraDono Aug. 5 at 2:10 AM
Momentum is real here. Eyes on this for a potential run. $CVKD
0 · Reply
SabrinaHo
SabrinaHo Aug. 5 at 2:01 AM
$CVKD Seeing signs of life again. On my radar for a bullish move.
0 · Reply
justiceforb_85
justiceforb_85 Aug. 5 at 2:01 AM
$CVKD when is the phase 3 trial for tecarfarin?
1 · Reply
TerryJoh
TerryJoh Aug. 5 at 1:54 AM
$CVKD I like the setup here. Undervalued gem with strong fundamentals.
0 · Reply
Latest News on CVKD
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

Aug 5, 2025, 6:00 AM EDT - 16 hours ago

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Jun 12, 2025, 8:00 AM EDT - 7 weeks ago

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

Jun 4, 2025, 8:00 AM EDT - 2 months ago

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

May 15, 2025, 7:30 AM EDT - 2 months ago

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 8:00 AM EDT - 3 months ago

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

Apr 17, 2025, 9:40 AM EDT - 3 months ago

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Apr 3, 2025, 8:00 AM EDT - 4 months ago

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Mar 13, 2025, 4:05 PM EDT - 5 months ago

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

Mar 4, 2025, 8:00 AM EST - 5 months ago

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

ABT

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Feb 6, 2025, 9:00 AM EST - 6 months ago

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Feb 5, 2025, 9:00 AM EST - 6 months ago

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 9, 2025, 8:44 AM EST - 7 months ago

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Dec 31, 2024, 8:00 AM EST - 7 months ago

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Dec 18, 2024, 9:00 AM EST - 8 months ago

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Nov 19, 2024, 9:00 AM EST - 9 months ago

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

Nov 12, 2024, 9:00 AM EST - 9 months ago

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Nov 7, 2024, 9:00 AM EST - 9 months ago

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Nov 1, 2024, 8:00 PM EDT - 9 months ago

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

Oct 24, 2024, 9:00 AM EDT - 10 months ago

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

Oct 23, 2024, 9:00 AM EDT - 10 months ago

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

Sep 23, 2024, 4:15 PM EDT - 11 months ago

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Aug 22, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Aug 20, 2024, 9:00 AM EDT - 1 year ago

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA ELUT EUDA GDTC GOSS GOVX IMRN

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

Aug 14, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

Aug 6, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

ABT

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

Jun 11, 2024, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients

Jun 3, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients

ABT

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 23, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

May 9, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Apr 11, 2024, 4:30 PM EDT - 1 year ago

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Apr 9, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

Mar 11, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference

Feb 26, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Feb 8, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions

Jan 31, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Jan 24, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

Jan 4, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target

Dec 19, 2023, 9:00 AM EST - 1 year ago

Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target

Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization

Dec 12, 2023, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization

Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023

Nov 30, 2023, 4:15 PM EST - 1 year ago

Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023

Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update

Nov 9, 2023, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference

Oct 9, 2023, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference

Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress

Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)

Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 28, 2023, 4:15 PM EDT - 2 years ago

Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update

Aug 10, 2023, 9:00 AM EDT - 2 years ago

Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update

Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases

Aug 1, 2023, 9:00 AM EDT - 2 years ago

Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases

Joby099
Joby099 Aug. 6 at 1:27 AM
$QBTS $CVKD $EQ $NVA $KULR
0 · Reply
PaidBashar
PaidBashar Aug. 5 at 10:44 PM
$CVKD wen financing
0 · Reply
BioTuesdays
BioTuesdays Aug. 5 at 2:11 PM
$CVKD has announced clinical trial initiation plans for its lead late-stage candidate, tecarfarin, for the treatment of patients with end-stage kidney disease (ESKD) transitioning to dialysis https://biotuesdays.com/2025/08/05/cadrenal-reveals-clinical-trial-plans-for-tecarfarin-in-eskd/
0 · Reply
Joby099
Joby099 Aug. 5 at 12:02 PM
$QBTS $CVKD $EQ $NVA $KULR
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 5 at 10:53 AM
WATCHLIST AUG 05 2025. $CVKD Cadrenal Therapeutics Announced Trial Initiation Plans For Tecarfarin For End-stage Kidney Disease Patients Who Are Transitioning To Dialysis. Enrollment Is Planned To Begin Later This Year And Will Include Patients With And Without Atrial Fibrillation $DD DuPont De Nemours On Track For Nov. 1 Spinoff Date For Electronics Business Creating New Independent, Publicly Traded Electronics Company "Qnity Electronics, Inc." $ATKR Atkore CEO Bill Waltz Announces Retirement Plans; Board Of Directors Begins Search For New Chief Executive $PRTA Chardan Capital Maintains Buy on Prothena Corp, Maintains $18 Price Target $PRAA PRA Group shares are trading higher after the company reported a year-over-year increase in Q2 GAAP EPS results and better-than-expected Q2 sales results.
0 · Reply
AnnaDona
AnnaDona Aug. 5 at 2:13 AM
$CVKD Volume picking up today. Heavy volume pouring in — something's brewing.
1 · Reply
MayraDono
MayraDono Aug. 5 at 2:10 AM
Momentum is real here. Eyes on this for a potential run. $CVKD
0 · Reply
SabrinaHo
SabrinaHo Aug. 5 at 2:01 AM
$CVKD Seeing signs of life again. On my radar for a bullish move.
0 · Reply
justiceforb_85
justiceforb_85 Aug. 5 at 2:01 AM
$CVKD when is the phase 3 trial for tecarfarin?
1 · Reply
TerryJoh
TerryJoh Aug. 5 at 1:54 AM
$CVKD I like the setup here. Undervalued gem with strong fundamentals.
0 · Reply
TracyNaj
TracyNaj Aug. 5 at 1:51 AM
Just grabbed more shares today. Undervalued gem with strong fundamentals. $CVKD
0 · Reply
BarbaraPor
BarbaraPor Aug. 5 at 1:49 AM
$CVKD People will wish they bought earlier. Accumulation happening — breakout soon?
0 · Reply
DoraSchee
DoraSchee Aug. 5 at 1:46 AM
Chart looks too good to ignore. One catalyst away from liftoff. $CVKD
0 · Reply
TeresaPere
TeresaPere Aug. 5 at 1:44 AM
Looks like accumulation to me. Massive upside potential in play. $CVKD
0 · Reply
MichelleYou
MichelleYou Aug. 5 at 1:36 AM
$CVKD Riding this one up. Looks coiled and ready to move.
0 · Reply
DorothyBurn
DorothyBurn Aug. 5 at 1:32 AM
This is setting up nicely. Watch this level closely — could fly. $CVKD
0 · Reply
KristinaEas
KristinaEas Aug. 5 at 1:30 AM
Seeing signs of life again. Strong momentum building here. $CVKD
0 · Reply
KristinaEas
KristinaEas Aug. 5 at 1:28 AM
$CVKD Volume picking up today. This one is gearing up for a breakout.
0 · Reply
GenevieveSto
GenevieveSto Aug. 5 at 1:25 AM
$CVKD Riding this one up. Heavy volume pouring in — something's brewing.
0 · Reply
BarbaraJack
BarbaraJack Aug. 5 at 1:21 AM
Just grabbed more shares today. Accumulation happening — breakout soon? $CVKD
0 · Reply
LynseyNob
LynseyNob Aug. 5 at 1:19 AM
$CVKD Feels like something big is coming. Heavy volume pouring in — something's brewing.
0 · Reply
MelissaPere
MelissaPere Aug. 5 at 1:17 AM
$CVKD Chart looks too good to ignore. This chart looks ready to explode.
0 · Reply